en · de · es · pt
assay-notes.peptides6608.com › Topic › Dihexa Chemical Identity And Origin — Deep Dive

Dihexa Chemical Identity And Origin — Deep Dive

By Editorial Desk · published 2026-02-24 · last reviewed 2026-03-20 · Topic

CAS Registry Number comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Dihexa Chemical Identity and Origin

Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.

Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.

Research Evidence and Regulation

Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.

Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.

Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Dihexa Background and Classification

Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.

The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.

Related pages on this site

Laboratory Handling and Quality Control

In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.

Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.

Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.

Dihexa Background and Research Context

Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.

The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.

Further detail

=== Since Silk Road === From late 2013 through to 2014, new markets started launching with regularity, such as the Silk Road 2.0, run by the former Silk Road site administrators, as well as the Agora marketplace. Such launches were not always a success; in February 2014 Utopia, the highly anticipated market based on Black Market Reloaded, opened only to shut down eight days later following rapid actions by Dutch law enforcement. February 2014 also marked the short lifespans of Black Goblin Market and CannabisRoad, two sites which closed after being deanonymized without much effort. November 2014 briefly shook the darknet market ecosystem, when Operation Onymous, executed by the United States' FBI and UK's National Crime Agency, led to the seizure of 27 hidden sites, including Silk Road 2.0, one of the largest markets at the time, as well 12 smaller markets and individual vendor sites. By September 2014, Agora was reported to be the largest market, avoiding Operation Onymous; as of April 2015, Agora has gone on to be the largest overall marketplace, with more listings than the Silk Road at its height. Further market diversification occurred in 2015, as did further developments around escrow and decentralization. In March 2015, the Evolution marketplace performed an "exit scam", stealing escrowed bitcoins worth $12 million, half of the ecosystem's listing market share at that time. The closure of Evolution led to users redistributing to Black Bank and Agora.

Magnetic nanoparticles (MNPs) are a class of nanoparticle that can be manipulated using magnetic fields. Such particles commonly consist of two components, a magnetic material, often iron, nickel and cobalt, and a chemical component that has functionality. While nanoparticles are smaller than 1 micrometer in diameter (typically 1–100 nanometers), the larger microbeads are 0.5–500 micrometer in diameter. Magnetic nanoparticle clusters that are composed of a number of individual magnetic nanoparticles are known as magnetic nanobeads with a diameter of 50–200 nanometers. Magnetic nanoparticle clusters are a basis for their further magnetic assembly into magnetic nanochains. The magnetic nanoparticles have been the focus of much research recently because they possess attractive properties which could see potential use in catalysis including nanomaterial-based catalysts, biomedicine and tissue specific targeting, magnetically tunable colloidal photonic crystals, microfluidics, magnetic resonance imaging, magnetic particle imaging, data storage, environmental remediation, nanofluids, optical filters, defect sensor, magnetic cooling and cation sensors.

=== Single Convention on Narcotic Drugs, 1961 === The adoption of this convention is regarded as a milestone in the history of the international drug ban. The Single Convention codified all existing multilateral treaties on drug control and extended the existing control systems to include the cultivation of plants that were grown as the raw material of narcotic drugs. The principal objectives of the convention are to limit the possession, use, trade, distribution, import, export, manufacture, and production of drugs exclusively for medical and scientific purposes, and to address drug trafficking through international cooperation to deter and discourage drug traffickers. The convention also established the International Narcotics Control Board, merging the Permanent Central Board and the Drug Supervisory Board. The 1961 Convention seeks to control over 116 drugs that it classifies as narcotic. These include:

Homebake (or home-bake) is a slang name most commonly used in Australia, and New Zealand for non-prescription opioids. The term refers to a crude mix of opioid class of drugs such as heroin, morphine and monoacetylated derivatives produced from pharmaceutical morphine tablets or morphine that has been produced through the demethylation of codeine when it is difficult to obtain heroin.

Sources: en.wikipedia.org

Supporting material

=== Additional toxic effects === Apart from its mutagenic nature, thiotepa can exert skin toxicity, such as redness and hyperpigmentation. Other less frequent symptoms are peeling skin and mucositis. These effects can be unified under the term of "toxic erythema of chemotherapy". Due to thiotepa's excretion via sweat, skin exposure is especially high in regions with a high density of sweat glands. Namely, symptoms are more abundant at skin folds, the groin, armpits, and generally obstructed skin where accumulation of sweat can take place. The symptoms can be minimized by washing the skin with water and preventing the use of soap and moisturizers, together with preventing obstructions of the skin, 36 hours after thiotepa administration. Thiotepa's ability to cross the blood-brain barrier can lead to diseases related to the white brain matter and neurotoxic symptoms such as memory deficits, dizziness, blurred vision, and others. Additionally, neurotoxicity and mucositis are the main dose-limiting factors in high-dose treatment (whereas the main dose-limiting factor, myelosuppression, is remedied by applying transplantation of bone marrow). Other general adverse effects of chemotherapy with thiotepa are infections, diarrhea, nausea, vomiting, oedema and hair loss. In-vivo experiments in animals displayed additional and potentially important toxicities. Thiotepa has been found to negatively affect fertility in male and female mice by interfering with spermatogenesis and impairing ovarian function, respectively.

=== Bifurcated and over-coordinated hydrogen bonds in water === A single hydrogen atom can participate in two hydrogen bonds. This type of bonding is called "bifurcated" (split in two or "two-forked"). It can exist, for instance, in complex organic molecules. It has been suggested that a bifurcated hydrogen atom is an essential step in water reorientation. Acceptor-type hydrogen bonds (terminating on an oxygen's lone pairs) are more likely to form bifurcation (it is called overcoordinated oxygen, OCO) than are donor-type hydrogen bonds, beginning on the same oxygen atom's hydrogen atoms.

Nearly all elements in the periodic table form binary bromides. The exceptions are decidedly in the minority and stem in each case from one of three causes: extreme inertness and reluctance to participate in chemical reactions (the noble gases, with the exception of xenon in the very unstable XeBr2); extreme nuclear instability hampering chemical investigation before decay and transmutation (many of the heaviest elements beyond bismuth); and having an electronegativity higher than bromine's (oxygen, nitrogen, fluorine, and chlorine), so that the resultant binary compounds are formally not bromides but rather oxides, nitrides, fluorides, or chlorides of bromine. (Nonetheless, nitrogen tribromide is named as a bromide as it is analogous to the other nitrogen trihalides.) Bromination of metals with Br2 tends to yield lower oxidation states than chlorination with Cl2 when a variety of oxidation states is available. Bromides can be made by reaction of an element or its oxide, hydroxide, or carbonate with hydrobromic acid, and then dehydrated by mildly high temperatures combined with either low pressure or anhydrous hydrogen bromide gas. These methods work best when the bromide product is stable to hydrolysis; otherwise, the possibilities include high-temperature oxidative bromination of the element with bromine or hydrogen bromide, high-temperature bromination of a metal oxide or other halide by bromine, a volatile metal bromide, carbon tetrabromide, or an organic bromide. For example, niobium(V) oxide reacts with carbon tetrabromide at 370 °C to form niobium(V) bromide.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

Has dihexa been tested in humans?

Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.

Network